Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 370

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 370
---
 personalized nutrition and lifestyle plans based on their health goal. These sessions aimed to review the most significant outcomes of the Rewell report, addressing user queries regarding their results, assessing the user’s current routines and habits, proposing improvements, and educating on the impact of these habits on their health. The objective of these sessions was to set small, achievable, long -termgoals to improve or maintain microbiome health and prevent disease development. This educational approach ensures the report’s findings are used actively by rather than solely being read and stored away. 183 We expect that the first commercial use of our AI Agents may begin as early as 2026, subject to continued progress in foundational large language models (LLMs), regulatory developments, and successful internal testing and validation. We acknowledge that AI technologies are rapidly evolving, and our timelines are subject to acceleration or delay based on technological and regulatory developments. Our AI Agents will be built on third -partyinfrastructure, including LLMs and other machine learning technologies developed by external vendors. While these models provide significant potential to increase the scalability and efficiency of personalized healthcare, they also introduce critical risks, including bias, errors in medical interpretation, and the risk of overreliance by us and the end consumers of our products on automated outputs. All outputs generated by AI Agents will remain subject to human oversight, especially where medical recommendations are involved. Licensed professionals will review and approve AI -drivenguidance as appropriate, specifically relating to medical diagnosis, and users will have access to human support if needed. Oversight will be maintained through established protocols and professional networks to ensure quality, safety, and compliance with evolving regulatory standards. For more information, see “ Risk Factors — Risks Related to Our Business and Stra tegy — Our fu ture AI Agents business will significantly depend upon third -party infrastructures, including language models and other AI technologies, which are subject to developing regulatory frameworks.” Before the transition to the business -to-business-to-consumermodel, the specialists prepared a personalized habits plan based on user lifestyle data, health risk indicators from their results, and health goals, which range from achieving a healthy weight, to optimizing physical performance and immunology, and mitigating disease development to impact longevity. These insights and methodologies will help to develop AI Agents, which will deliver personalized recommendations and action plans at scale. These action plan will set achievable objectives that would foster changes in intestinal microbiome results, thus benefiting our user’s health. Further, users would receive supplementary materials, including recipe books and other personalized content to support habit changes.